UK health service recommends Humira for ocular condition

The National Health Service in England has provided interim guidance recommending that Humira (adalimumab) be routinely commissioned for adults with severe refractory uveitis.

The interim policy is in place pending the publication of a technology appraisal from the UK’s health watchdog, the National Institute for Health and Care Excellence, which is expected in July.

Uveitis is a group of inflammatory eye conditions which can be caused either by infection or abnormal activation of the immune system in the eye. The global market for treatments in this area is growing strongly and estimated to be worth around half a billion dollars.